This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

E. Michael Van Buskirk, MD; Frederick T. Fraunfelder, MD
Portland, Ore

Arch Ophthalmol. 1981;99(4):696.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—There is increasing evidence of systemic side effects secondary to topical ocular administration of timolol maleate for the treatment of glaucoma.^1,2 These systemic side effects are essentially the same as those seen from systemically administered β-blockers.³ Topical ocular timolol in occasional persons produces plasma drug concentrations sufficient to cause systemic β-adrenoceptor blocking effects. This may result from a seemingly low ocular dose because the expected 75% reduction from oral timolol for "first-pass" hepatic metabolism does not occur. With topical ocular administration of timolol, about 80% of the eyedrop is absorbed from the nasal mucosa and enters almost directly into the vascular system.⁴ The potential for increased systemic side effects from timolol is increased in the elderly, who often have lax distensible conjunctival fornices that permit greater retention of topical ocularly administered drugs.⁵

During the past two years, 140 cases of patients with adverse . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?